SV

Street Verdict

Analyst Scorecard

METROPOLIS · NSE

Metropolis Healthcare Limited

₹597.45

+1.90% (+₹11.15)

Prev. close

₹586.3

Volume

2,23,299

Delivery %

47.1%

As of

18 Sept 2026

Price history

₹597.45+₹73 (+13.92%) · 3M
10 Jun 2026 → 18 Sept 2026
₹602.1₹520.1510 Jun03 Jul03 Aug26 Aug18 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on Metropolis Healthcare Limited in the last 90 days.

Fundamentals

About Metropolis Healthcare Limited

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India and internationally. The company offers routine and specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; clinical trial research, hospital lab management, and home collection services; radiology services, including X-ray, sonography and ECG; and next-generation sequencing services. It also provides diagnostic services for oncology, chronic and infectious diseases, gastroenterology, neurology, nephrology, and women and child health, as well as various health checkup and laboratory services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, mobile app, website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.

Details

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Ms. Ameera Sushil Shah

Headquarters

Mumbai

Employees

4,484

Key stats

Market cap

₹12,394.33 Cr

P/E ratio (TTM)

61.4

Dividend yield

0.34%

EPS (TTM)

₹9.73

Beta (1Y · daily vs NIFTY 50)

0.41

Beta (5Y · monthly vs NIFTY 50)

0.81

Shares float

10.60 Cr

EPS · quarter ended Jun 2026

₹2.73

Upcoming earnings

04 Nov 2026

Financial Performance

01 · Financials

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹-20%0%20%40%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

FY21 growth needs FY20 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

051015₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

01122₹-100%-50%0%50%13 Feb 2017 Feb 2121 Feb 2223 Feb 2317 Nov 2311 Nov 2519 May 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-200%0%200%400%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

0 Cr100 Cr200 Cr300 Cr400 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹997.99 Cr₹1,228.34 Cr₹1,148.21 Cr₹1,207.71 Cr₹1,331.20 Cr₹1,645.85 Cr
EBITDA₹298.05 Cr₹376.32 Cr₹303.52 Cr₹291.69 Cr₹318.11 Cr₹417.44 Cr
₹183.10 Cr₹214.18 Cr₹142.88 Cr₹127.82 Cr₹144.97 Cr₹190.02 Cr
Diluted EPS₹8.95₹10.42₹6.95₹6.22₹7.04₹9.19

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,000.00 Cr₹1,521.00 Cr₹1,495.00 Cr₹1,547.00 Cr₹1,859.00 Cr₹2,131.00 Cr
₹112.27 Cr₹378.56 Cr₹266.38 Cr₹197.06 Cr₹204.13 Cr₹231.91 Cr
Stockholders' equity₹706.00 Cr₹886.00 Cr₹988.00 Cr₹1,096.00 Cr₹1,331.00 Cr₹1,513.00 Cr

CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹249.00 Cr₹253.00 Cr₹247.00 Cr₹264.00 Cr₹263.00 Cr₹351.00 Cr
Investing cash flow₹61.70 Cr₹-735.05 Cr₹46.79 Cr₹-89.41 Cr₹-201.06 Cr₹-223.13 Cr
₹-33.00 Cr₹163.00 Cr₹-292.00 Cr₹-181.00 Cr₹-87.00 Cr₹-115.00 Cr
Capital expenditure₹-28.27 Cr₹-30.66 Cr₹-52.63 Cr₹-63.76 Cr₹-68.61 Cr₹-51.18 Cr
End cash position₹386.59 Cr₹65.98 Cr₹68.83 Cr₹62.62 Cr₹39.48 Cr₹54.78 Cr

Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22–Jun 22(2Q)Sep 22–Dec 22(2Q)Mar 23–Jun 23(2Q)Sep 23–Dec 23(2Q)Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25–Sep 25(2Q)Dec 25Mar 26–Mar 26(2Q)Jun 26
Promoter50.33%49.50%49.79%49.76%49.75%49.74%49.67%49.62%49.43%49.40%48.90%48.89%48.88%48.87%48.86%
Public49.67%50.50%50.21%50.24%50.25%50.26%50.33%50.38%50.57%50.60%51.10%51.11%51.12%51.13%51.14%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%—
Metropolis Healthcare Limited₹12,094.56 Cr₹585.559.67.9912.6%0.15+23.6%-71.1%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

IPO documents

Annual reports

Show all 8

Concall transcripts

Show all 13

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

11 indices

BSE Healthcare· 0.4%Nifty Smallcap 500· 0.2%Nifty Total Market· 0.0%BSE 1000 MULTICAP EQUAL SIZE WEIGHTED (25%)BSE 250 MICROCAPBSE NEXT 500BSE SmallCapBSE Smallcap 500BSE Total MarketNifty Microcap 250Nifty Smallcap250 Quality 50

NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.

METROPOLIS

Metropolis Healthcare: Franklin Templeton Acquires 0.36% Additional Stake

Franklin Templeton Mutual Fund acquired an additional 0.358% stake in Metropolis Healthcare, purchasing 742,409 shares through an open market transaction on September 4, 2026. This acquisition increases Franklin Templeton's total holding to 5.100% of Metropolis Healthcare's total voting capital.

12 days ago·Read at InvestyWise
METROPOLIS

Metropolis Healthcare Bets On AI, Expansion And Deeper Penetration

Business Today · 12 days ago